Procalcitonin is a blood marker used primarily to detect bacterial infections and guide decisions about antibiotic treatment. In healthy people, procalcitonin circulates at nearly undetectable levels, below 0.05 ng/mL. When a bacterial infection takes hold, levels can rise dramatically, sometimes exceeding 10 ng/mL in severe cases like septic shock. This predictable response makes it one of the most practical tools clinicians have for distinguishing bacterial infections from viral ones and for deciding when antibiotics can safely be stopped.
How Procalcitonin Works in the Body
Under normal circumstances, procalcitonin is a precursor molecule produced by thyroid cells and eventually converted into the hormone calcitonin, which helps regulate calcium. During a systemic bacterial infection, something entirely different happens: cells in the lungs and intestines begin producing procalcitonin in large quantities, triggered by bacterial toxins and the body’s own inflammatory signaling molecules. This “emergency” procalcitonin floods into the bloodstream but is never converted into calcitonin, so it stays measurable as a distinct signal.
The timing of this response is one of procalcitonin’s key advantages. Levels begin rising 6 to 12 hours after a bacterial infection starts and climb steadily in the hours that follow. Once the infection is under control, procalcitonin has a consistent half-life of 20 to 24 hours, meaning levels drop by roughly half each day. That predictable decline gives clinicians a real-time window into whether treatment is working.
Bacterial vs. Viral Infections
The main clinical value of procalcitonin is its ability to help separate bacterial infections from viral ones. Bacterial toxins drive procalcitonin production upward. Viruses do the opposite: they trigger the release of interferons, immune signaling molecules that actively suppress procalcitonin production. So a patient with a high fever and a low procalcitonin level is more likely dealing with a virus than a bacterium. Research in febrile infants has confirmed this pattern, showing that even when a bacterial infection is present, a concurrent viral illness pulls procalcitonin levels down compared to bacterial infection alone.
This distinction matters because antibiotics work against bacteria but do nothing for viruses. A procalcitonin test can help avoid unnecessary antibiotic prescriptions, which reduces side effects for patients and slows the broader problem of antibiotic resistance.
Procalcitonin Levels and What They Suggest
Clinicians interpret procalcitonin results along a spectrum rather than as a simple positive or negative. The general framework looks like this:
- Below 0.05 ng/mL: Normal, no significant bacterial activity
- 0.05 to 0.49 ng/mL: Possible localized infection
- 0.5 to 1.99 ng/mL: Suggestive of sepsis
- 2 to 9.99 ng/mL: Suggestive of severe sepsis
- Above 10 ng/mL: Consistent with septic shock
For lower respiratory tract infections specifically, the FDA has approved a tiered algorithm. Antibiotics are strongly discouraged when procalcitonin is below 0.1 ng/mL and discouraged between 0.1 and 0.25 ng/mL. Above 0.25 ng/mL, antibiotics are recommended, and above 0.5 ng/mL, they are strongly recommended. These thresholds help guide both the decision to start antibiotics and the decision to stop them.
Guiding Antibiotic Duration
One of procalcitonin’s most impactful uses is telling clinicians when it’s safe to stop antibiotics sooner. Because levels drop by about 50% each day once an infection is controlled, serial measurements can signal that the body is winning the fight. A clinical trial at a U.S. medical center found that procalcitonin-guided therapy reduced the median antibiotic course for pneumonia from 7 days to 6, and for flare-ups of chronic obstructive pulmonary disease from 4 days to 3. Those reductions may sound modest, but across thousands of patients they translate into significantly less antibiotic exposure.
The Surviving Sepsis Campaign guidelines recommend using procalcitonin to shorten antibiotic duration in sepsis patients. The approach is more cautious on the other end of the decision: the Infectious Diseases Society of America discourages using a single baseline procalcitonin result to decide whether to start antibiotics for community-acquired pneumonia or hospital-acquired pneumonia. In other words, procalcitonin is better established as a tool for stopping antibiotics than for deciding whether to begin them.
How It Compares to C-Reactive Protein
C-reactive protein (CRP) is the other widely used blood marker for infection and inflammation, and the two tests have different strengths. Procalcitonin tends to be more sensitive, meaning it’s better at catching true infections and less likely to miss them. CRP tends to be more specific, meaning a positive result is more reliable as confirmation. In studies of very low birth weight infants, CRP emerged as the stronger independent predictor of sepsis in statistical models, while procalcitonin maintained higher sensitivity (73% vs. 48%) but lower specificity (60% vs. 85%).
The correlation between the two markers is weak, which means they’re measuring somewhat different aspects of the body’s response. In practice, clinicians often use them together rather than choosing one over the other. Procalcitonin’s advantage is its more specific link to bacterial infection and its predictable timeline of rise and fall, which makes serial tracking more informative.
When Procalcitonin Rises Without Infection
Procalcitonin is not a perfect indicator of bacterial infection. Several non-infectious conditions can push levels up, which is important context for interpreting results. Major surgery, particularly cardiac procedures involving bypass, triggers an inflammatory cascade that raises procalcitonin. Levels after cardiac surgery often peak on the first postoperative day, with average values around 3.2 ng/mL, well into the range that would normally suggest severe infection.
Severe trauma and burns also cause significant elevations. In studies of burn patients, procalcitonin was elevated regardless of whether infection developed, though higher values (above 2.1 ng/mL) were associated with worse outcomes. Multi-organ injuries in children produced average levels near 4 ng/mL on admission, and levels above 20 ng/mL were seen in those who did not survive. Notably, procalcitonin could not reliably distinguish between septic shock and hemorrhagic shock, which limits its usefulness in emergency trauma settings where both possibilities are on the table.
Special Considerations in Newborns
Interpreting procalcitonin in newborns requires extra caution. All babies, healthy and infected alike, experience a natural rise in procalcitonin during the first 24 hours of life, peaking around the one-day mark before declining over the next 24 hours. This physiological surge makes it difficult to use standard adult thresholds during the first two days after birth.
Gestational age adds another layer of complexity. Premature infants have lower baseline procalcitonin levels than full-term babies, and their immune systems respond differently to infection. The bacteria that cause illness in newborns, such as group B Streptococcus, are also different from typical adult pathogens. There is no consensus on the optimal threshold for a positive result in neonates, which means clinicians rely on procalcitonin as one piece of a larger diagnostic picture rather than as a standalone test.